Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
Jing Ma,Chao Dong,Yan-Zhen Cao,Bin-Lin Ma
DOI: https://doi.org/10.2147/BCTT.S390017
2023-01-17
Breast Cancer: Targets and Therapy
Abstract:Jing Ma, 1 Chao Dong, 1 Yan-Zhen Cao, 2 Bin-Lin Ma 1 1 Department of Breast and Thyroid Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830000, People's Republic of China; 2 Pathology Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, 830000, People's Republic of China Correspondence: Bin-Lin Ma, Department of Breast and Thyroid Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, No. 789, Suzhou East Street, Xinshi District, Urumqi, 830000, People's Republic of China, Tel/Fax +86 991 7819082, Email Objective: To detect the activation of the EGFR and mTOR signaling pathways in the triple negative breast cancer cell line MDA-MB-468 and investigate the inhibitory effect of gefitinib, an epidermal growth factor receptor inhibitor, and everolimus, a target protein inhibitor of rapamycin, on triple negative breast cancer cells. Methods: Triple negative human breast cancer MDA-MB-468 cells were cultured and blank control group, single EGFR inhibitor gefitinib group, single mTOR inhibitor everolimus group, and two drug combination group were set up respectively to detect the effects of single and combined drugs on cell proliferation activity, cell cycle and apoptosis, and the expression of EGFR and mTOR signal pathway proteins in cell lines after single and combined drug intervention was detected again by Western blot. Results: The level of EGFR and p-mTOR protein in triple negative breast cancer was higher than in non triple negative breast cancer ( P < 0.05). The level of mTOR, S6K1, p-EGFR, p-S6K1 was significantly increased when treated with EGF (0ng/mL, 10ng/mL, 100ng/mL) for 1h, compared to without EGF stimulation ( P < 0.05). The level of p-EGFR, p-mTOR, p-S6K1 protein increased significantly when the cells were exposed to EGF for 2h, respectively ( P < 0.05). EGFR inhibitor gefitinib alone and the mTOR inhibitor everolimus alone could significantly inhibit the proliferation of human triple negative breast cancer MDA-MB-468 cells in a dose-dependent manner ( P < 0.05). The level of p-4EBP1 protein in EGFR and mTOR signal pathway was significantly increased after the intervention of gefitinib alone, everolimus alone, and the combination of two drugs ( P < 0.05). Conclusion: EGFR and mTOR signaling pathways can be activated in triple negative breast cancer; Both the EGFR inhibitor gefitinib alone and the mTOR inhibitor everolimus alone can significantly inhibit the proliferation of human triple negative breast cancer MDA-MB-468 cells. The combination of the EGFR inhibitor gefitinib and the mTOR inhibitor everolimus may achieve anti-tumor effect similar to that of single drug by reducing the drug dose. Keywords: triple-negative breast cancer, epidermal growth factor receptor, EGFR, mammalian target of rapamycin, mTOR, anti-tumor efficacy, ribosomal protein S6 kinase, RPS6K, 4E binding protein 1, 4EBP1 Breast cancer is one of the most common malignant tumors in women. It is the most frequently diagnosed cancer in the vast majority of the countries (154 of 185) and is also the leading cause of cancer death in over 100 countries. 1 Although the total mortality rate has been declining due to improvements in diagnostic techniques and refinements in treatment modalities in many developed nations in the past decades, mortality from advanced types of breast cancers has remained at a high level. Most patients present with an unresectable disease, and the current treatment options of chemotherapy and radiotherapy are unsatisfactory. New strategies are needed for the treatment of this disease to improve patient survival rates. Breast cancer is highly heterogeneous, with different types of breast cancers demonstrating considerable heterogeneity despite a common tissue of origin. In clinical practice, breast cancers are usually divided into the following subtypes according to the status of different molecular biomarkers: 2 estrogen receptor- (ER) or progesterone receptor- (PR) positive (also known as luminal types), human epidermal growth factor receptor 2- (HER2) positive with or without ER and PR positivity (also known as the HER2 overexpressed type), and triple-negative breast cancer (TNBC), which is defined by the absence of ER/PR expression and HER2 amplification. Among them, TNBC is the most aggressive subtype, accounting for 15–20% of breast cancers and encompassing more than one molecular subtype. In contrast to the ER/PR-positive and/or HER2-negative molecular subtypes, TNBC has the clinical characteristics of rapid progression, early onset of metastasis, and unresponsiveness to available hormonal and anti-HER2-targeted therapies.<sup -Abstract Truncated-